Key result
Deletion or pharmacological inhibition of DNA-PKcs attenuated angiotensin II-induced vascular remodeling and hypertension by preventing Drp1-mediated mitochondrial fragmentation in vascular smooth muscle cells.
Why the study?
The role and mechanism of DNA-PKcs in angiotensin II-induced vascular remodeling remain obscure.
Cytoplasmic DNA-PKcs in vascular smooth muscle cells drives Ang II-induced vascular remodeling and hypertension via mitochondrial fragmentation, highlighting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
DNA-PKcs targeting may mitigate vascular remodeling; leaves open clinical translation pending human trials.
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a novel instigator for mitochondrial dysfunction, and plays an important role in the pathogenesis of cardiovascular diseases. However, the role and mechanism of DNA-PKcs in angiotensin II (Ang II)-induced vascular remodeling remains obscure. Rat aortic smooth muscle cells (SMC) and VSMC-specific DNA-PKcs knockout (DNA-PKcsΔVSMC) mice were employed to examine the role of DNA-PKcs in vascular remodeling and the underlying mechanisms. Blood pressure of mice was monitored using the tail-cuff and telemetry methods. The role of DNA-PKcs in vascular function was evaluated using vascular relaxation assessment. In the tunica media of remodeled mouse thoracic aortas, and renal arteries from hypertensive patients, elevated DNA-PKcs expression was observed along with its cytoplasmic translocation from nucleus, suggesting a role for DNA-PKcs in vascular remodeling. We then infused wild-type (DNA-PKcsfl/fl) and DNA-PKcsΔVSMC mice with Ang II for 14 days to establish vascular remodeling, and demonstrated that DNA-PKcsΔVSMC mice displayed attenuated vascular remodeling through inhibition of dedifferentiation of VSMCs. Moreover, deletion of DNA-PKcs in VSMCs alleviated Ang II-induced vasodilation dysfunction and hypertension. Mechanistic investigations denoted that Ang II-evoked rises in cytoplasmic DNA-PKcs interacted with dynamin-related protein 1 (Drp1) at its TQ motif to phosphorylate Drp1S616, subsequently promoting mitochondrial fragmentation and dysfunction, as well as reactive oxygen species (ROS) production. Treatment of Irbesartan, an Ang II type 1 receptor (AT1R) blocker, downregulated DNA-PKcs expression in VSMCs and aortic tissues following Ang II administration. Our data revealed that cytoplasmic DNA-PKcs in VSMCs accelerated Ang II-induced vascular remodeling by interacting with Drp1 at its TQ motif and phosphorylating Drp1S616 to provoke mitochondrial fragmentation. Maneuvers targeting DNA-PKcs might be a valuable therapeutic option for the treatment of vascular remodeling and hypertension.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied Vascular remodeling and hypertension. DNA-PKcs deletion or inhibition (NU7441, irbesartan) vs. Wild-type or vehicle control was evaluated on Vascular remodeling and hypertension (systolic blood pressure, medial thickness, collagen content). Deletion or pharmacological inhibition of DNA-PKcs attenuated angiotensin II-induced vascular remodeling and hypertension by preventing Drp1-mediated mitochondrial fragmentation in vascular smooth muscle cells.
Synapse has enriched 10 related papers. Consider them for comparative context: